

C1  
cont

(a) immunizing said mammal with an inoculum comprising a vehicle containing a recombinant DNA molecule comprising a DNA sequence that contains (i) a sequence encoding a CETP immunogen linked to (ii) a promoter sequence that controls the expression of said CETP immunogen DNA sequence in said mammal, said CETP immunogen comprising an antigenic carrier to which is covalently bonded one or more immunogenic polypeptides comprising a CETP amino acid residue sequence of about 10 to about 30 residues, said amino acid residue sequence corresponding to an immunogenic sequence of said endogenous CETP; and

(b) maintaining said immunized mammal for a time period sufficient for the production of antibodies that bind to CETP, thereby producing antibodies.

---

C2

2. (amended) The process of claim 3 wherein the blood of said mammal contains CETP.

---

3. (twice amended) A process for increasing the concentration of HDL cholesterol in the blood of a mammal whose blood contains cholesteryl ester transfer protein (CETP) that comprises the steps of:

C3

(a) immunizing said mammal with an inoculum comprising a vehicle containing a recombinant DNA molecule comprising a DNA sequence that contains (i) a sequence encoding a CETP immunogen linked to (ii) a promoter sequence that controls the expression of said CETP immunogen DNA sequence in said mammal, said CETP immunogen comprising an antigenic carrier to which is covalently bonded one

or more immunogenic polypeptides comprising a CETP amino acid residue sequence of about 10 to about 30 residues;

C3  
CMT

(b) maintaining said immunized mammal for a time period sufficient for said CETP immunogen to be expressed and for the production of antibodies that bind to CETP and lessen the transfer of cholesteryl esters from HDL, thereby increasing the HDL concentration; and

(c) repeating said immunizing step until the HDL cholesterol value in the blood of said mammal is increased by about 10 percent or more relative to the HDL cholesterol value prior to said first immunization step.

---

C4

4. (amended) The process according to claim 1 wherein said immunizing step is repeated.

5. (amended) The process according to claim 3 wherein said immunizing step is repeated at intervals of about 3 to about 6 months.

6. (amended) The process according to claim 3 wherein said recombinant DNA molecule encodes human CETP as at least one of said one or more immunogenic polypeptides.

7. (amended) The process according to claim 3 wherein said recombinant DNA molecule encodes rabbit CETP as at least one of said one or more immunogenic polypeptides.

C4  
CMT

8. (amended) The process according to claim 3 wherein said CETP immunogen comprises one immunogenic polypeptide fused to an exogenous antigenic carrier polypeptide.

---

10. (amended) The process according to claim 8 wherein said recombinant DNA molecule encodes a fusion protein in which said exogenous antigenic carrier is fused to the carboxy-terminus of said one immunogenic polypeptide.

---

C5

11. (amended) The process according to claim 8 wherein the carboxy-terminus of said exogenous antigenic carrier is fused to the amino-terminus of said one immunogenic polypeptide.

---

C6

15. (amended) The process according to claim 3 wherein at least one of said one or more immunogenic polypeptides has the amino acid residue sequence of SEQ ID NOs: 29 or 50.

---

C7

17. (amended) A human inoculum that comprises a recombinant DNA molecule comprising a DNA sequence that contains (i) a sequence encoding a human CETP immunogen linked to (ii) a promoter sequence that controls the expression of said CETP immunogen DNA sequence in a human, said recombinant DNA molecule contained in an effective amount in a pharmaceutically acceptable vehicle, said CETP immunogen comprising an antigenic carrier to which is covalently bonded one or more

C7  
Cmt immunogenic polypeptides comprising a CETP amino acid residue sequence of about 10 to about 30 residues.

---

C8  
22. (twice amended) The process according to claim 1 wherein said one or more immunogenic polypeptides are each independently of a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 29, 32, 33, 34, 35, 36, 37 and 50.

---

23. (twice amended) The process according to claim 3 wherein said one or more immunogenic polypeptides are each independently of a sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 29, 32, 33, 34, 35, 36, 37 and 50.

---

C9  
24. (amended) The process according to claim 6 wherein at least one of said one or more human CETP immunogenic polypeptides comprises a sequence selected from the group consisting SEQ ID NOs: 8-13 and 29.

---

25. (amended) The process according to claim 7 wherein said rabbit CETP immunogenic polypeptide comprises a sequence selected from the group consisting SEQ ID NOs: 2-7 and 50.

C<sup>9</sup>  
C<sup>9</sup>  
26. (amended) The process according to claim 3 wherein said recombinant DNA molecule encodes monkey CETP as at least one of said immunogenic polypeptides.

---

27. (twice amended) The process according to claim 26 wherein said monkey CETP immunogenic polypeptide comprises a sequence selected from the group consisting SEQ ID NOs: 32-36 and 37.

---

C<sup>10</sup>  
28. (twice amended) The inoculum according to claim 17 wherein at least one of said one or more immunogenic polypeptides is of a sequence selected from the group consisting of SEQ ID NOs: 4, 10, and 29.

---

C<sup>11</sup>  
29. (amended) A recombinant DNA molecule comprising a DNA sequence that contains (i) a sequence encoding a cholesteryl ester transfer protein (CETP) immunogen linked to (ii) a promoter sequence that controls the expression of said CETP immunogen DNA sequence in a mammal, said CETP immunogen being comprised of an exogenous antigenic carrier to which is covalently bonded one or more immunogenic polypeptides of a CETP amino acid residue sequence of about 10 to 30 residues.

---

C<sup>12</sup>  
31. (twice amended) The recombinant DNA according to claim 29 wherein at least one of said one or more immunogenic polypeptides is of a sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 29, 32, 33, 34, 35, 36, 37 and 50.

---